Sélection · Santé

Big pharma

Par InspectStocksPublished 14 oct. 202613 companies0 follower

The largest drugmakers, selling prescription medicines worldwide.

Regroupées avec l’aide d’un modèle d’IA et relues par notre rédaction. La ligne sous chaque entreprise indique pourquoi elle figure ici.

Download image

Cartes Niveaux

Les cours sont ceux de la clôture du 11 nov. 2026, issus du flux de la bourse IEX.

Grade mix

A 7B 3C 3

Revenue growing

12 of 12

Free cash flow growing

9 of 13

Median price move, 1 year

+34,0 %

Sort by

LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap 1,35T $USP/E 46,67
1 437,79 $US+42,2 %1Y
Since added +23,2 %
A+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
En amélioration
Revenue
86,5B $US+45,5 %
Profit
27,6B $US+49,8 %
Free cash flow
19,7B $US+112,1 %
Discuss
Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
JNJJohnson & Johnson
Drug manufacturers generalMarket cap 674,9B $USP/E 42,54
280,34 $US+47,5 %1Y
Since added +12,8 %
A+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
Contrasté
Revenue
99,3B $US+7,8 %
Profit
16,1B $US-35,9 %
Free cash flow
20,6B $US+5,1 %
Discuss
Why it is here: Sells prescription medicines for cancer and immune disorders
ABBVAbbVie Inc.
Drug manufacturers generalMarket cap 521,2B $USP/E 50,75
294,87 $US+30,2 %1Y
Since added +7,5 %
B+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
En amélioration
Revenue
66B $US+10,7 %
Profit
10,3B $US+333,1 %
Free cash flow
18,9B $US-4,1 %
Discuss
Why it is here: Sells medicines for immune, neurological and cancer conditions
MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap 362,9B $USP/E 150,20
147,20 $US+65,7 %1Y
Since added +3,7 %
A
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Solide
Getting better
Contrasté
Revenue
67,4B $US+4,9 %
Profit
2,5B $US-87,1 %
Free cash flow
14,7B $US+13,0 %
Discuss
Why it is here: Sells prescription medicines and vaccines for people and animals
NVSNovartis AG
Drug manufacturers generalMarket cap 306B $USPas de PER (perte d’exploitation)
160,36 $US+23,6 %1Y
Since added +12,6 %
A
Croissance et trésorerie
Croissance forte
Business quality
Contrastée
Getting better
En nette amélioration
Revenue
56,7B $US+9,6 %
Profit
-46M $USNo comparable year
Free cash flow
17,6B $US+8,3 %
Discuss
Why it is here: Sells prescription medicines
AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap 289,7B $USP/E 28,36
185,49 $US+115,2 %1Y
Since added +19,0 %
B+
Croissance et trésorerie
Croissance forte
Business trend
En ralentissement
Business quality
Forte
Getting better
En nette amélioration
Revenue
62,4B $US+7,3 %
Profit
10,2B $US+45,3 %
Free cash flow
11,8B $US+18,4 %
Discuss
Why it is here: Sells prescription medicines
NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap 182,8B $USP/E 11,84
41,10 $US-15,4 %1Y
Since added +8,0 %
C+
Croissance et trésorerie
En croissance
Business trend
En accélération
Business quality
Forte
Getting better
En amélioration
Revenue
50,3B $US+5,7 %
Profit
17,1B $US+9,1 %
Free cash flow
8,9B $US-20,1 %
Discuss
Why it is here: Sells diabetes and obesity medicines
PFEPFIZER INC
Drug manufacturers generalMarket cap 167,9B $USP/E 42,07
29,45 $US+21,4 %1Y
Since added +3,8 %
C
Croissance et trésorerie
Croissance forte
Business trend
En contraction
Business quality
Solide
Getting better
Contrasté
Revenue
63,6B $US+1,3 %
Profit
4B $US-59,0 %
Free cash flow
11,8B $US+13,6 %
Discuss
Why it is here: Sells prescription medicines and vaccines
BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap 128,6B $USP/E 13,95
62,92 $US+34,0 %1Y
Since added +11,0 %
C+
Croissance et trésorerie
En croissance
Business trend
Stable
Business quality
Forte
Getting better
En nette amélioration
Revenue
50B $US+4,2 %
Profit
9,2B $US+53,1 %
Free cash flow
9,3B $US-39,3 %
Discuss
Why it is here: Sells prescription medicines for cancer and immune conditions
SNYSanofi
Drug manufacturers generalMarket cap 59,1B $USP/E 6,81
48,43 $US-3,0 %1Y
Since added +23,9 %
B
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Contrastée
Getting better
En amélioration
Revenue
53,5B $US+11,6 %
Profit
4,7B $US-54,2 %
Free cash flow
8,1B $US+22,5 %
Discuss
Why it is here: Sells prescription medicines and vaccines
GSKGSK plc
Drug manufacturers generalMarket cap 109,2B $USP/E 13,60
50,60 $US+8,9 %1Y
Since added +9,3 %
A+
Croissance et trésorerie
Croissance forte
Business quality
Forte
Getting better
En nette amélioration
Revenue
43,8B $US+4,1 %
Profit
7,7B $US+122,0 %
Free cash flow
8,6B $US+24,0 %
Discuss
Why it is here: Sells prescription medicines and vaccines worldwide
AMGNAmgen Inc.
Drug manufacturers generalMarket cap 253,2B $USP/E 27,14
468,13 $US+43,1 %1Y
Since added +13,4 %
A+
Croissance et trésorerie
Croissance forte
Business trend
Stable
Business quality
Forte
Getting better
En amélioration
Revenue
38,9B $US+8,2 %
Profit
9,4B $US+34,1 %
Free cash flow
9,6B $US-17,0 %
Discuss
Why it is here: Develops and sells medicines and biosimilars for serious diseases
TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap 33,5B $USP/E 48,79
20,86 $US+50,1 %1Y
Since added +12,5 %
A
Croissance et trésorerie
Croissance forte
Business quality
Contrastée
Getting better
Contrasté
Revenue
29,8B $USNo comparable year
Profit
259,4M $USNo comparable year
Free cash flow
5,5B $US+1,1 %
Discuss
Why it is here: Sells prescription medicines and vaccines globally

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.